Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* provide written informed consent,~* male or female 18 years of age or greater; women of child bearing potential must use adequate contraception~* symptomatic AF/AFL for more than 3 hours and less than 7 days (168 hours), as dated by symptoms~* AF/AFL documented by ECG at the start of study drug administration~Exclusion Criteria:~* Systolic blood pressure \<100 mmHg.~* Average heart rate \<50 bpm.~* Average QTcF (Fridericia correction) \>440 ms.~* Average QRS interval \>140 ms.~* Paced atrial or ventricular rhythm on ECG.~* Serum potassium \<3.5 meq/L (may be corrected prior to randomization).~* Received another intravenous Class I or Class III antiarrhythmic drug within prior 3 days.~* received amiodarone (oral or IV) in prior 3 months.~* Clinical evidence or history of acute coronary syndrome within 30 days prior to randomization.~* Aortic stenosis with aortic valve area equal to or less than 1.0 cm2.~* Rheumatic mitral stenosis with valve area of \<1.5 cm2.~* Untreated hyperthyroidism.~* Acute pericarditis.~* AF/AFL as a result of surgery within the last 7 days~* History of failed electrical cardioversion~* History of polymorphic ventricular tachycardia (PVT, e.g. torsades de pointes).~* History or family history of long QT syndrome.~* History of ventricular tachycardia requiring drug or device therapy.~* History of NYHA Heart Failure Class 3 or 4 or recent (within 1 month) onset of heart failure not related to rapid ventricular response AF.~* Ejection fraction (EF) of 35% or less.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vanoxerine 200mg (Type: EXPERIMENTAL): vanoxerine HCl 200mg single dose (2x 100 mg oral capsule)
- placebo (Type: PLACEBO_COMPARATOR): placebo to match vanoxerine oral capsule
- vanoxerine 300mg (Type: EXPERIMENTAL): vanoxerine HCl 300 mg single dose (3x 100mg oral capsules)
- vanoxerine 400mg (Type: EXPERIMENTAL): vanoxerine HCl 400 mg single dose (4x 100 mg oral capsules)

Based on this trial design, predict the completion outcome and termination type (if applicable).